B
Blandine Deux
Researcher at French Institute of Health and Medical Research
Publications - 7
Citations - 454
Blandine Deux is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Bone metastasis & Breast cancer. The author has an hindex of 5, co-authored 7 publications receiving 411 citations. Previous affiliations of Blandine Deux include University of Lyon & Claude Bernard University Lyon 1.
Papers
More filters
Journal ArticleDOI
The HIF-1–Inducible Lysyl Oxidase Activates HIF-1 via the Akt Pathway in a Positive Regulation Loop and Synergizes with HIF-1 in Promoting Tumor Cell Growth
Floriane Pez,Frédéric Dayan,Jérôme Durivault,Bastien Kaniewski,Géraldine Aimond,Gabrielle S. Le Provost,Blandine Deux,Philippe Clézardin,Pascal Sommer,Jacques Pouysségur,Caroline Reynaud +10 more
TL;DR: Mechanistic investigations revealed that LOX activated the PI3K (phosphoinositide 3-kinase)-Akt signaling pathway, thereby upregulating HIF-1α protein synthesis in a manner requiring LOX-mediated hydrogen peroxide production, suggesting that Hif-1/LOX mutual regulation is a pivotal mechanism in the adaptation of tumor cells to hypoxia.
Journal ArticleDOI
Cancer Cell Expression of Autotaxin Controls Bone Metastasis Formation in Mouse through Lysophosphatidic Acid-Dependent Activation of Osteoclasts
Marion David,Marion David,Estelle Wannecq,Françoise Descotes,Silvia Jansen,Blandine Deux,Blandine Deux,Johnny Ribeiro,Johnny Ribeiro,Claire Marie Serre,Claire Marie Serre,Sandra Grès,Nathalie Bendriss-Vermare,Mathieu Bollen,Simone Saez,Junken Aoki,Jean Sébastien Saulnier-Blache,Philippe Clézardin,Philippe Clézardin,Olivier Peyruchaud,Olivier Peyruchaud +20 more
TL;DR: A new role for LPA is demonstrated as a factor that stimulates directly cancer growth and metastasis, and osteoclast differentiation, and is targeted as a potential new therapeutic approach to improve the outcome of patients with bone metastases.
Journal ArticleDOI
Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
Penelope D. Ottewell,Blandine Deux,Hannu Mönkkönen,Simon S. Cross,Robert E. Coleman,Philippe Clézardin,Ingunn Holen +6 more
TL;DR: This is the first study to show that sequential treatment with clinically relevant doses of doxorubicin, followed 24 h later by zoledronic acid, reduces intraosseous but not extraOSseous growth of BO2 breast tumors.
Journal ArticleDOI
Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo.
Benjamin Gibert,Benedicte Eckel,V Gonin,David Goldschneider,Joanna Fombonne,Blandine Deux,Patrick Mehlen,A-P Arrigo,Philippe Clézardin,Chantal Diaz-Latoud +9 more
TL;DR: It is shown by qRT–PCR that Hsp27 gene is overexpressed in a large fraction of the metastatic breast cancer area in 53 patients and that in vivo it correlated with a decreased ability of breast cancer cells to metastasise and grow in the skeleton.
Journal Article
Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases.
Philippe Kischel,Akeila Bellahcene,Blandine Deux,Virginie Lamour,Rowan Dobson,Edwin De Pauw,Philippe Clézardin,Vincenzo Castronovo +7 more
TL;DR: In vivo experiments showed that an antibody against CD9 delays homing of B02 cells in bone marrow, slowing down bone destruction and reveals a potential implication of CD9 in the formation of bony metastases from breast cancer cells.